EUCTR2022-002520-13-Outside-EU/EEA进行中（未招募）1 期
Phase IV Multi-center, Prospective, Interventional, Post-marketing Study in Hemophilia B Patients in India receiving RIXUBIS as On-demand or Prophylaxis Under Standard Clinical Practice
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. The subject or legally authorized representative (in case of study participants <18 years of age) gave written informed consent to participate in the study.
- •2. Subject has hemophilia B.
- •3. Subject is defined as previously-treated patient (PTP): ?
- •- Subject aged = 6 years that has been previously treated with plasma-derived and/or recombinant FIX concentrate(s) for a minimum of 150 EDs.
- •- Subject aged < 6 years that has been previously treated with plasma-derived and/or recombinant FIX concentrate(s) for a minimum of 50 EDs.
- •4. Subject has no evidence of a history of FIX inhibitors.
- •5. Subject is human immunodeficiency virus negative (HIV-); or HIV+ with stable disease and CD4+ count = 200 cells/mm3, as confirmed by central laboratory at screening.
- •6. Subject is hepatitis C virus negative (HCV-) by antibody or PCR testing (if positive, antibody titer will be confirmed by PCR), as confirmed by central
- •laboratory at screening; or HCV+ with chronic stable hepatitis.
- •7. The subject is willing and able to comply with the requirements of the protocol.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 5
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subject has known hypersensitivity or presence of any contraindication to RIXUBIS or its excipients including hamster protein.
- •2. Subject has evidence of an ongoing or recent thrombotic disease, fibrinolysis or disseminated intravascular coagulation (DIC).
- •3. Subject has a history of FIX inhibitors with a titer = 0.6 Bethesda Units (BU) (as determined by the Nijmegen modification of the Bethesda assay or the assay, employed in the respective local laboratory) at any time prior to screening.
- •4. Subject has a detectable FIX inhibitor at screening, with a titer = 0.6 BU as determined by the Nijmegen modification of the Bethesda assay in the central laboratory.
- •5. Subject has severe chronic liver disease as evidenced by, but not limited to, any of the following: International Normalized Ratio (INR) > 1.4 hypoalbuminemia,
- •portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices.
- •6. Subject has severe chronic hepatic dysfunction [eg, = 5 times upper limit of normal alanine aminotransferase (ALT), as confirmed by central laboratory at screening, or a documented INR > 1.5].
- •7. Subject has severe renal impairment (serum creatinine > 2.0 mg/dL), as confirmed by central laboratory at screening.
- •8. Subject has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia B.
- •9. Subject’s platelet count is < 100,000/mL. 10. Subject has a clinically significant medical, psychiatric, or cognitive illness, or recreational drug/alcohol use that, in the opinion of the investigator, would affect subject’s safety or compliance.
- •11. Subject is currently receiving, or is scheduled to receive during the course of the study, an immunomodulating drug (eg, corticosteroid agents at a dose equivalent to hydrocortisone greater than 10 mg/day, or a-interferon) other than antiretroviral chemotherapy.
- •12. Subject has participated in another clinical study involving an IP or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
- •13. Subject is a family member or employee of the investigator.
研究者
相似试验
进行中（未招募）
4 期
A Post-marketing study receiving RIXUBIS as on-demand or Prophylaxis under standard clinical practice in patients with Hemophilia BCTRI/2018/07/014754Baxalta Innovations GmbH
进行中（未招募）
4 期
Safety of ADVATE in previously treated Indian patients for treatment of mild , moderate and severe bleeding episodes in Haemophilia ACTRI/2021/10/037406Baxalta US Inc50
进行中（未招募）
1 期
A Study of ADVATE in People With Hemophilia A in IndiaHemophilia AEUCTR2022-004149-11-Outside-EU/EEATakeda Biopharmaceuticals India Pvt. Ltd.50
进行中（未招募）
不适用
Multicenter, interventional, single-arm, phase IV study evaluating tolerability of Eribulin and its relationship with a set of polymorphisms in an unselected population of female patients with metastatic breast cancerPatients with metastatic breast cancerEUCTR2013-004600-19-ITAzienda Ospedaliera Fatebenefratelli e Oftalmico - Milano, Italy
招募中
4 期
Phase IV study to assess the safety, efficacy and immunogenicity of MJ Pharma-BIOSULIN�® 30:70CTRI/2020/03/024054M J Biopharm Private Limited